Concord Biotech

Concord Biotech Limited is an Indian biotechnology and pharmaceutical company headquartered in Ahmedabad, Gujarat. Its core business is the development and manufacture of fermentation-based biopharmaceutical active pharmaceutical ingredients, or APIs, which are supplied to pharmaceutical markets in India and overseas. Rather than primarily presenting itself as a consumer-facing medicine brand, Concord Biotech operates mainly as a specialized API and biopharmaceutical manufacturing company serving drug manufacturers and regulated healthcare markets. The company was founded in 2000 by Sudhir Vaid, a former director at Ranbaxy Laboratories. An early technical milestone was its development of tacrolimus, an immunosuppressant used in transplant medicine. Concord Biotech is described as the first company in India, and the second company globally, to develop this anti-immunosuppressant through its own capabilities. This helped establish the company’s initial specialization in fermentation-derived therapeutic ingredients and provided a foundation for later expansion across additional treatment categories. Concord Biotech manufactures products for several therapy segments. These include immunosuppressants, oncology-related ingredients, antifungal products, antibacterial products and anthelmintic products. The company’s portfolio is therefore connected to both chronic and specialized-care medicines, including therapies where reliable API supply, manufacturing consistency and regulatory compliance are particularly important. Its business model emphasizes production capabilities and pharmaceutical supply relationships rather than a broad retail brand identity. The company’s manufacturing footprint includes two facilities in Gujarat. Its plant at Dholka, near Ahmedabad, has approval from the United States Food and Drug Administration, reflecting the company’s participation in internationally regulated pharmaceutical supply chains. A second facility is located at Limbasi in Kheda district. Together, these sites support Concord Biotech’s fermentation-based production activities and its ability to serve domestic and international customers. Ownership of Concord Biotech changed several times during its development. In 2004, investor Rakesh Jhunjhunwala acquired approximately 14 percent of the company. In 2005, Hyderabad-based Matrix Laboratories acquired a 55 percent stake by purchasing part of the holdings of Sudhir Vaid and Rakesh Jhunjhunwala. After Mylan acquired Matrix Laboratories, Mylan subsequently sold its Concord Biotech stake back to Vaid and Jhunjhunwala in 2009. Private-equity investor Quadria Capital acquired a 20 percent stake in 2016. Quadria later exited its investment through Concord Biotech’s initial public offering in 2023, while Rare Enterprises, associated with Rakesh Jhunjhunwala, was reported to hold a substantial stake. Concord Biotech’s current identity is consequently that of an Indian specialist pharmaceutical manufacturer with international supply reach. Its differentiation rests on fermentation expertise, a portfolio of technically demanding APIs, regulated manufacturing infrastructure and experience in supplying ingredients used in immunosuppressive, oncology and anti-infective medicines. Public reference material provides limited detail about its consumer products, advertising campaigns, current executives and post-listing commercial strategy; those fields are therefore left unfilled where specific evidence is unavailable.

Concord Biotech was established in 2000 in India by Sudhir Vaid, who had previously served as a director at Ranbaxy Laboratories. From its beginning, the company focused on fermentation-based pharmaceutical manufacturing rather than on the development of a broad consumer medicines portfolio. Its early work centered on technically specialized biopharmaceutical ingredients, including tacrolimus, an immunosuppressant used in transplant-related treatment. The company’s development of tacrolimus was a significant early technical achievement. Concord Biotech is described as the first Indian company and the second company worldwide to develop this anti-immunosuppressant. This capability helped define the company’s position in the pharmaceutical supply chain and supported its later expansion into other fermentation-derived APIs. In 2004, investor Rakesh Jhunjhunwala acquired approximately 14 percent of Concord Biotech. The ownership structure changed the following year when Matrix Laboratories, based in Hyderabad, acquired a 55 percent stake by purchasing portions of the holdings of Sudhir Vaid and Rakesh Jhunjhunwala. Matrix Laboratories was subsequently acquired by Mylan. After that transaction, Mylan sold its interest in Concord Biotech back to Vaid and Jhunjhunwala in 2009. Concord Biotech continued to develop its manufacturing and therapeutic portfolio. Its products came to cover immunosuppressive, oncology, antifungal, antibacterial and anthelmintic applications. The company established or operated two manufacturing sites in Gujarat: one at Dholka near Ahmedabad and another at Limbasi in Kheda district. The Dholka facility received approval from the United States Food and Drug Administration, an important qualification for participation in regulated international pharmaceutical markets. In 2016, private-equity investor Quadria Capital acquired a 20 percent stake in the company. Quadria later disposed of its entire investment through Concord Biotech’s initial public offering in 2023. The company’s ownership history therefore includes founder involvement, strategic pharmaceutical-industry ownership, private-equity investment and a transition to public-market ownership. The reference material also identifies Rare Enterprises as holding a 24 percent stake. Today, Concord Biotech is characterized as an Indian biopharmaceutical manufacturer supplying fermentation-based APIs worldwide. Its business remains centered on manufacturing expertise and pharmaceutical customers rather than on direct-to-consumer branding. Publicly available reference material establishes its principal facilities, therapeutic categories and ownership milestones, but does not provide enough verified information for a detailed account of current management, individual product launch dates, advertising campaigns or later corporate developments.

• 2023

  Initial public offering

  [1]Concord Biotechen.wikipedia.org

  Quadria Capital sold its entire stake through Concord Biotech’s initial public offering.

• 2016

  Quadria Capital invests

  [1]Concord Biotechen.wikipedia.org

  Quadria Capital acquired a 20 percent stake in Concord Biotech.

• 2009

  Mylan sells its stake

  [1]Concord Biotechen.wikipedia.org

  After Mylan acquired Matrix Laboratories, it sold its Concord Biotech stake back to Sudhir Vaid and Rakesh Jhunjhunwala.

• 2005

  Matrix Laboratories becomes a major shareholder

  [1]Concord Biotechen.wikipedia.org

  Matrix Laboratories acquired a 55 percent stake by purchasing portions of the holdings of Sudhir Vaid and Rakesh Jhunjhunwala.

• 2004

  Rakesh Jhunjhunwala acquires a stake

  [1]Concord Biotechen.wikipedia.org

  Rakesh Jhunjhunwala acquired approximately 14 percent of Concord Biotech.

• 2000

  Company founded

  [1]Concord Biotechen.wikipedia.org

  Sudhir Vaid founded Concord Biotech in India after serving as a director at Ranbaxy Laboratories.

• 2000

  Tacrolimus development

  [1]Concord Biotechen.wikipedia.org

  Concord Biotech developed tacrolimus and was described as the first Indian and second global company to develop this anti-immunosuppressant.

A specialist Indian biopharmaceutical API manufacturer built around fermentation technology, regulated production and international pharmaceutical supply.

• Immunosuppressant API

  Tacrolimus

  Tacrolimus is an immunosuppressive pharmaceutical ingredient associated with Concord Biotech’s early technical development. The company is described as the first in India and the second worldwide to develop this anti-immunosuppressant, making tacrolimus an important marker of its fermentation and biopharmaceutical capabilities.

• Biopharmaceutical active pharmaceutical ingredients

  Immunosuppressant APIs

  Concord Biotech manufactures fermentation-based APIs for immunosuppressive therapies. These ingredients support medicines used in specialized treatment areas, including transplant-related care, and represent one of the company’s core therapeutic segments.

• Biopharmaceutical active pharmaceutical ingredients

  Oncology APIs

  The company’s oncology portfolio consists of pharmaceutical ingredients used in cancer-related medicines. Public reference material identifies oncology as one of Concord Biotech’s principal therapy segments but does not specify a complete product-by-product list.

• Antifungal, antibacterial and anthelmintic ingredients

  Anti-infective APIs

  Concord Biotech also produces fermentation-based ingredients for antifungal, antibacterial and anthelmintic therapies. These categories broaden the company beyond immunosuppression and oncology while retaining its focus on pharmaceutical manufacturing inputs.

• 2023

  Public-market transition through an initial public offeringOther

  Background

  Concord Biotech moved toward public-market ownership, providing an exit route for Quadria Capital, which had acquired a 20 percent stake in 2016.

  Action taken

  The company completed an initial public offering, through which Quadria Capital sold its entire investment.

  Aftermath

  The transaction marked a new ownership phase for Concord Biotech as a publicly traded Indian pharmaceutical company.

  Source

• 2023

  Quadria Capital exits Concord Biotech through its initial public offering[1]Concord Biotechen.wikipedia.org

  M&A · Other

  Quadria Capital sold its entire stake in Concord Biotech through the company’s 2023 initial public offering.

1. 1Concord Biotechen.wikipedia.org
2. 2Lupin launches generic drug used for prevention of organ rejection in kidney transplant in USbusiness-standard.com
3. 3Lupin launches generic immunosuppressant drug in US- Moneycontrol.commoneycontrol.com
4. 4Lupin launches Mycophenolate Mofetil Tabletsbusiness-standard.com
5. 5Lupin launches Mycophenolate Mofetil tablets in US- Moneycontrol.commoneycontrol.com
6. 6Lupin launches Mycophenolate Mofetil Tablets USPequitybulls.com
7. 7Lupin launches Mycophenolic Acid Delayed-Release Tabletsbusiness-standard.com